Pancreatic cancer is characterised by several key genetic alterations such as activating mutations in the KRAS oncogene or inactivation in the CDKN2A/INK4A tumour suppressor gene that result in abnormal cell signalling and altered control of cell proliferation (Jones et al, 2008). Here, CDKN2A is linked to pancreatic neoplasm.